Although Aβ and tau are used to define AD as a unique neurodegenerative disease, it is now being considered that disease modifiers other than Aβ and tau may act in concert to regulate disease progression and manifestation of clinical symptoms. The gene discussed is MAPT; the disease is Alzheimer disease.